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Tomography Analysis
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Background: Non-uniform strut distribution (NSD) is an important factor predis-
posing to intimal hyperplasia through decreased local drug delivery and increased
scaffold recoil after BVS implantation. The aim of this study was to evaluate, using
optical coherence tomography (OCT), the impact of underlying plaque morphology on
strut distribution of bioresorbable vascular scaffolds (BVS 1.1) versus metallic ever-
olimus eluting stents (EES).
Methods: Among 39 patients who underwent elective percutaneous coronary inter-
vention (PCI) (n¼20 in BVS group, n¼19 in EES group), a total of 1200 post-PCI
OCT frames (BVS: 590 frames; EES: 610 frames) were analyzed. NSD was deﬁned as
a frame with maximum inter-strut angle i 120.
Results: The percentage of frames with NSD was signiﬁcantly higher in the BVS
group (26.1% [154/590] vs. 19.0% [116/ 610], p¼0.003). In the EES group the cal-
cium arc in frames with NSD was not signiﬁcantly different compared to that in
frames with uniform strut distribution (USD) (34.644.4 vs. 35.647.1, p¼0.83).
However, in the BVS group the arc of calcium was signiﬁcantly greater in frames with
NSD as compared to those with USD (85.262.6 vs. 21.041.7, p< 0.0001). In
multivariable analysis, after adjustment for post-dilatation balloon size and maximum
inﬂation pressure, a calcium arc >75 was identiﬁed as an independent predictor of
NSD after BVS implantation (odds ratio: 12.1, 95% conﬁdence interval: 7.9-18.8, p<
0.001).
Conclusions: The presence of calciﬁed plaque behind BVS struts appears to be an
independent predictor for NSD. For calciﬁed lesions, meticulous lesion preparation,
including use of dedicated devices, may help prevent NSD after BVS stent
implantation.
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Background: There are limited data regarding clinical outcomes of patients with
complex lesions treated with bioresorbable vascular scaffolds (BVS) compared to new
generation drug eluting stents (DES).
Methods: We analyzed 1-year clinical outcome data of 432 consecutive patients
treated with either new-generation DES or BVS between May 2008 and May 2014.
Propensity score (PS) matching was applied prior to comparisons between the two
groups. Primary outcome was major adverse cardiac events (MACE) which was
deﬁned as all-cause death, follow-up myocardial infarction (MI) and target-vessel
revascularization (TVR).
Results: A total of 432 patients were included in this study. After PS matching,
96 patients treated with BVS (BVS group) and 96 patients treated with DES
(DES group) were selected. Lesion characteristics were similar between two
groups. Over 80% of lesions in both cohorts were ACC/AHA lesion classiﬁcation
type B2 and C (83.3% in BVS vs. 85.2% in DES, p¼0.68). Pre and post-dila-
tation in BVS group were performed more frequently compared to that in DES
group (100% vs. 72.1%, p< 0.01; 100% vs. 86.4%, p< 0.01), and maximum
inﬂation pressure after stenting in BVS group was higher than that in DES group
(21.15.1 atm vs. 18.45.1 atm, p< 0.01). There was no signiﬁcant difference in
the 1-year cumulative MACE incidence between the BVS and the DES group
(10.8% vs. 12.7%, p¼0.33). Similarly there was no signiﬁcant differences in the
composite endpoint of all-cause death and MI (3.6% vs. 4.5%, p¼0.30), TVR
(10.8% vs. 9.6%, p¼0.80) or target lesion revascularization (9.2% vs. 5.6%,
p¼0.51). There was 1 episode of deﬁnite stent thrombosis in BVS group and 1 in
EES group.
Conclusions: In the present all-comers cohort with a high proportion of complex
lesions, the 1-year MACE in the BVS group was similar to that of patients treated
with new generation DES. In the BVS group, however, meticulous lesion prepa-
ration including dedicated balloons may be needed to achieve similar clinical
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Background: While everolimus-eluting bioresorbable vascular scaffolds (BVS) were
studied in healthy swine, effects of inﬂammation and atherosclerosis on degradation of
BVS and vascular behaviour remain to be determined.
Methods: Of 15 farm-bred swine, 8 received streptozotocin to induce diabetes mel-
litus (DM), then a high cholesterol diet was given to all 15 swine. Nine months later,
32 coronary Absorb BVS (Abbott Vascular, Santa Clara, CA) were implanted under
angiographic guidance. Histology, serology and polymer degradation analysis was
performed. Results of degradation were compared to controls from normal, non-
atherosclerotic swine (n ¼ 6/ time point).
Results: Degradation was similar in diseased and normal healthy swine and was
determined only by implanted duration. It was not affected by DM, lipid accumulation
in the neointima, or inﬂammation (Fig). Struts were completely covered at both 3 and
6 months follow-up, irrespective of DM and atherosclerosis. Likewise, DM did not
affect histological scores. Importantly, all disease groups showed marked neointimal
atherosclerosis, with focal lipid accumulation, irregular collagen distribution and
neointimal calciﬁcations. The latter was observed in various patterns, particularly
towards the lumen.Conclusions: In swine coronary arteries, DM, atherosclerosis and inﬂammation do
not affect BVS degradation or the vascular response to BVS. Both in DM and non-
DM, the neointima was equally associated with calciﬁcation, lipid accumulation and
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Background: Compared to drug eluting stents, for bioresorbable vascular scaffolds
(BVS, Abbott Vascular Inc., Santa Clara, CA) sizing may be more important in terms
of malapposition and fracture because of smaller expansion limits. The registry aims7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
